Skip to content

Cancer Health Center

Font Size

Diagnosis and Staging

    Staging and evaluation of disease status is undertaken at diagnosis and performed again early in the course of chemotherapy and at the end of chemotherapy.

    Pretreatment Staging

    The diagnostic and staging evaluation is a critical determinant in the selection of treatment. Initial evaluation of the child with Hodgkin lymphoma includes the following:[1,2]

    Systemic symptoms

    The following three specific constitutional symptoms (B symptoms) correlate with prognosis and are considered in assignment of stage:

    Additional Hodgkin-associated constitutional symptoms without prognostic significance include the following:

    • Pruritus.
    • Alcohol-induced nodal pain.

    Physical examination

    • All node-bearing areas, including the Waldeyer ring, should be assessed by careful physical examination.
    • Enlarged nodes should be measured to establish a baseline for evaluation of therapy response.

    Laboratory studies

    • Hematological and chemical blood parameters show nonspecific changes that may correlate with disease extent.
    • Abnormalities of peripheral blood counts may include neutrophilic leukocytosis, lymphopenia, eosinophilia, and monocytosis.
    • Acute-phase reactants such as the erythrocyte sedimentation rate and C-reactive protein, if abnormal at diagnosis, may be useful in follow-up evaluation.

    Anatomic imaging

    Anatomic information from CT is complemented by PET functional imaging, which is sensitive in determining initial sites of involvement, particularly sites too small to be considered abnormal by CT criteria.

    Definition of bulky disease

    The posteroanterior chest radiograph remains important since the criterion for bulky mediastinal lymphadenopathy used in North American protocols is defined by the ratio of the diameter of the mediastinal lymph node mass to the maximal diameter of the rib cage on an upright chest radiograph; a ratio of 33% or higher is considered bulky. This definition is no longer used in some European protocols because it does not influence risk classification.

    The criteria for bulky peripheral (nonmediastinal) lymphadenopathy have varied per cooperative group study protocols from aggregate nodal masses exceeding 4 to 6 cm. This disease characteristic has not been consistently used among all groups for risk stratification.

      1|2|3|4|5|6

      Today on WebMD

      Colorectal cancer cells
      A common one in both men and women.
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
       
      Jennifer Goodman Linn self-portrait
      Blog
      what is your cancer risk
      HEALTH CHECK
       
      colorectal cancer treatment advances
      Video
      breast cancer overview slideshow
      SLIDESHOW
       
      prostate cancer overview
      SLIDESHOW
      lung cancer overview slideshow
      SLIDESHOW
       
      ovarian cancer overview slideshow
      SLIDESHOW
      Actor Michael Douglas
      Article